1672 — Ascletis Pharma Balance Sheet
0.000.00%
- HK$13.54bn
- HK$11.57bn
- CNY1.28m
Annual balance sheet for Ascletis Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2,714 | 2,501 | 2,482 | 2,299 | 1,948 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 48.2 | 67.4 | 29.3 | 19.7 | 9.26 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,830 | 2,632 | 2,545 | 2,333 | 1,971 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 84.6 | 77.9 | 73 | 68.5 | 57.2 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,067 | 2,830 | 2,657 | 2,491 | 2,125 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 73.8 | 91 | 108 | 141 | 153 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 85.4 | 101 | 117 | 149 | 158 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 2,982 | 2,729 | 2,540 | 2,342 | 1,966 |
| Total Liabilities & Shareholders' Equity | 3,067 | 2,830 | 2,657 | 2,491 | 2,125 |
| Total Common Shares Outstanding |